MAYO CLINIC

Lutetium Lu 177 dotatate demonstrated antitumor activity in patients with metastatic bronchopulmonary neuroendocrine tumors, achieving partial responses in 17% of patients in a real-world study.

A custom-built antisense oligonucleotide drug targeting the CHCHD10 gene mutation has slowed ALS progression by more than half in Dr. Rakesh Parekh, marking the first treatment for this specific genetic variant.

TREOS Bio has initiated OBERTO-202, a potentially registration-enabling Phase II trial evaluating PolyPEPI1018 combined with toripalimab and standard care in 140 patients with microsatellite stable metastatic colorectal cancer.

Arctx Medical received FDA Investigational Device Exemption approval to conduct a pivotal clinical trial of its Cool Catheter Kit in approximately 200 acute pancreatitis patients at up to 25 US hospitals.

Former FDA Commissioner Dr. Stephen Hahn has been appointed CEO of Nucleus RadioPharma, a contract development and manufacturing organization specializing in radiopharmaceuticals for targeted cancer therapy.

Ruxolitinib demonstrates sustained efficacy in polycythemia vera with 74% probability of maintaining primary composite response at 5-year follow-up in the RESPONSE trial.

Payer-specific biosimilar mandates create significant inventory management challenges and operational inefficiencies for academic and infusion centers, requiring substantial resources to coordinate care delivery.

iMDx has enrolled its first patient in the GraftAssureDx clinical trial, an observational study designed to validate a kitted transplant rejection monitoring test for kidney transplant recipients.

Ultromics raised $55 million in Series C funding to expand its FDA-cleared EchoGo platform for detecting heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis across US hospitals.

Radiopharm Theranostics has appointed Dr. Oliver Sartor, an internationally recognized medical oncologist specializing in prostate cancer and radiopharmaceutical therapies, to its Scientific Advisory Board.